Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM).’ The study aims to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN), enrolling approximately 1000 patients across 45 sites in the United States. This research is significant as it could provide insights into the relationship between eHC and rHTN, potentially influencing future treatment approaches.
The study is non-interventional, focusing on observational data collection. Patients will undergo a series of visits, including a screening, a fasting blood draw after taking dexamethasone, and further testing for those identified with eHC. This approach helps in understanding the prevalence of eHC in the specified patient group.
The study is designed as an observational cohort with a cross-sectional time perspective. It does not involve any allocation or masking, as it primarily seeks to gather data on the prevalence of eHC among patients with rHTN.
The study commenced on March 28, 2025, with the last update submitted on July 25, 2025. These dates are crucial as they indicate the study’s progress and ongoing data collection efforts.
From a market perspective, this study could impact Corcept Therapeutics’ stock performance positively if it uncovers significant findings that lead to new treatment avenues. Investor sentiment may be influenced by the potential for new therapeutic developments, especially in the context of resistant hypertension, a challenging condition to manage.
The study is currently recruiting, with further details available on the ClinicalTrials portal.